Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Older people

No benefit to daily aspirin in healthy older people

Despite widespread use of low-dose aspirin, a placebo-controlled trial of almost 20,000 people found no benefit of the drug in healthy older people.

old man pouring pills into his hand

Source: Shutterstock.com

Researchers have found that aspirin use in healthy older people does not prolong disability-free survival over a period of five years

Daily low-dose aspirin does not increase the duration of disability-free life in healthy older people, trial results published in the New England Journal of Medicine (16 September 2018) have shown[1].

The study involved 19,114 people in the United States and Australia with a median age of 74 years who did not have cardiovascular disease, dementia or physical disability. Of these, 9,525 participants were randomly assigned to receive 100mg of enteric-coated aspirin daily and 9,589 participants to an oral placebo. Individuals were followed-up for a median of 4.7 years.

The researchers found no significant difference between the two groups regarding the primary end point of death, dementia or persistent physical disability (21.5 versus 21.2 events per 1,000 person–years, respectively). However, the rate of major haemorrhage was significantly elevated by 38% among those taking aspirin compared with placebo (3.8% vs 2.8%).

The researchers noted that despite the widespread use of low-dose aspirin among older people, the evidence base is not strong enough to support this practice in individuals who have not previously experienced a cardiovascular event.

“Aspirin use in healthy [older people] did not prolong disability-free survival over a period of five years but led to a higher rate of major haemorrhage than placebo,” the team concluded.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20205506

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Clinical Pharmacokinetics

    Clinical Pharmacokinetics

    A practical guide to the use of pharmacokinetic principles in clinical practice. Includes case studies with questions and answers.

    £33.00Buy now
  • Essentials of Economic Evaluation in Healthcare

    Essentials of Economic Evaluation in Healthcare

    An introduction to economic evaluation specific to healthcare, for those with little or no knowledge of economics. Covers cost effectiveness, cost utility and cost benefit analysis.

    £33.00Buy now
  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Strategic Medicines Management

    Strategic Medicines Management

    A practical guide to influencing the availability of medicines, and policies of their use. Focuses on the strategic elements of medicines management.

    £33.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • old man pills ss 18

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.